Federal Register / Vol. 62, No. 5 / Wednesday, January 8, 1997 / Notices 1125

application addresses technologies

which encompass the broad category of

T-cell receptor and chimeric T-cell

technologies. As such, it is likely that

the technologies will have numerous

applications in the field of

immunotherapy and will potentially be

licensable to multiple applicants for a

variety of novel therapeutic approaches.

(portfolio: Gene-Based Therapies—

Therapeutics, delivery systems;

Cancer—Therapeutics,

immunomodulators and

immunostimulants; Cancer—

Therapeutics, vaccines; Cancer—

Therapeutics, gene therapy, genes)

Process for Producing Monoclonal

Antibodies Reactive With Human

Breast Cancer

J Schlom, D Colcher, M Nuti, PM Hand, FC

Austin (NCI)

Serial No. 06/330,959 filed 15 Dec 81

U.S. Patent No. 4,522,918 issued 11 June 85

Licensing Contact: Joseph Contrera, M.S.,

J.D., 301/496–7056 ext 244

Breast cancer is the second leading

cause of cancer death among women,

having only recently been surpassed by

lung cancer. The incidence rate has

remained somewhat steady, and is

currently about 108 per 100,000. This

invention describes a process to

produce antibodies from hybridoma

cultures for the detection, prognosis,

and treatment of human breast cancer.

These eleven antibodies are activated

only by tumor cells from human

mammary cells and not by apparently

normal human tissues. The isotopes of

ten and the antibodies are IgG of various

subclasses, and one is IgM. The

antibodies may be useful in five major

areas in the management of human

breast cancer: (1) The diagnosis of

primary and metastatic breast tumor

lesions by assay of human body fluids;

(2) the in-situ detection, via gamma

scanning, of primary or metastatic breast

tumor lesions; (3) the treatment of

primary or metastatic breast cancer

using one or a combination of the

antibodies either alone or coupled with

toxic drugs, compounds, or radioactive

isotopes; (4) use of the antibodies in the

staining of populations of human cells

in tissue sections from tumor lesions to

indicate the degree of malignancy of the

cell populations; and (5) the detection of

micro-lesions containing only a few

cells that could not be detected by

conventional staining techniques. A

patent for this invention has been issued

by the U.S. Patent and Trademark

Office. (portfolio: Cancer—Diagnostics,

in vitro, MAb based; Cancer—Research

Materials, MAb based)

Dated: December 23, 1996.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 97–332 Filed 1–7–97; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Allergy and

Infectious Diseases; Notice of Meeting:

Microbiology and Infectious Diseases

Research Committee

Pursuant to Public Law 92–463,

notice is hereby given of the meeting of

the Microbiology and Infectious

Diseases Research Committee, National

Institute of Allergy and Infectious

Diseases, on February 12–14, 1997 at the

Belmont Conference Center, Manor

House Conference Room, 6555 Belmont

Woods Road, Elkridge, Maryland.

The meeting will be open to the

public from 9 a.m. to 10 a.m. on

February 12, to discuss administrative

details relating to committee business

and for program review. Attendance by

the public will be limited to space

available. In accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

and section 10(d) of Public Law 92–463,

the meeting will be closed to the public

for the review, discussion, and

evaluation of individual grant

applications and contract proposals

from 10 a.m. until recess on February

12, from 9 a.m. until recess on February

13, and from 9 a.m. until adjournment

on February 14. These applications,

proposals and the discussions could

reveal confidential trade secrets or

commercial property such as patentable

material and personal information

concerning individuals associated with

the applications and proposals, the

disclosure of which would constitute a

clearly unwarranted invasion of

personal privacy.

Ms. Claudia Goad, Committee

Management Officer, National Institute

of Allergy and Infectious Diseases, Solar

Building, Room 3C26, National

Institutes of Health, Bethesda,

Maryland, 301–496–7601, will provide a

summary of the meeting and a roster of

committee members upon request.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

contact Ms. Goad in advance of the

meeting.

Dr. Gary Madonna, Scientific Review

Administrator, Microbiology and

Infectious Diseases Research Committee,

NIAID, NIH, Solar Building, Room

4C21, Rockville, Maryland 20892,

telephone 301–496–3528, will provide

substantive program information.

(Catalog of Federal Domestic Assistance

Program No. 93.856, Microbiology and

Infectious Diseases Research, National

Institutes of Health)

Dated: December 30, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 97–321 Filed 1–7–97; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Child Health and

Human Development; Notice of

Meeting of the National Advisory Child

Health and Human Development

Council

Pursuant to Public Law 92–463,

notice is hereby given of the meeting of

the National Advisory Child Health and

Human Development Council on

January 27–28, 1997. The meeting will

be held in Building 31, Conference

Room 10, National Institutes of Health,

Bethesda, Maryland. The meeting of the

Subcommittee on Planning will be open

on January 27. The Subcommittee

meeting will be held in Building 31,

Room 2A03, from 8:00 a.m. to 9:30 a.m.

to discuss program plans and the agenda

for the next Council meeting.

Attendance by the public will be limited

to space available.

The Council meeting will be open to

the public on January 27 from 10:00

a.m. until 5:30 p.m. The agenda

includes a report by the Director,

NICHHD, a report by the Mental

Retardation and Developmental

Disabilities Branch, an update on the

Inclusion of Children in Clinical

Research, and other business of the

Council. The meeting will be open on

January 28 upon completion of

applications at approximately 1:00 p.m.

to adjournment if any policy issues are

raised which need further discussion.

In accordance with the provisions set

forth in sections 552b(c)(4), and

552b(c)(6), Title 5, United States Code

and section 10(d) of Public Law 92–463,

the meeting of the full Council will be

closed to the public on January 28 from

8:00 a.m. to approximately 1:00 p.m. for

the review, discussion, and evaluation

of individual grant applications. These

applications and the discussions could

reveal confidential trade secrets or

commercial property such as patentable

material, and personal information

concerning individuals associated with

the applications, the disclosure of

which would constitute a clearly

unwarranted invasion of personal

privacy.

Ms. Mary Plummer, Executive

Secretary, NACHHD, 6100 Executive